Virtual Library

Start Your Search

Q. Zhao

Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      183P - Progression of central nervous system metastases in advanced non-small cell lung cancer patients effectively treated with first-generation EGFR-TKI (ID 395)

      12:30 - 13:00  |  Author(s): Q. Zhao

      • Abstract
      • Slides

      Central nervous system (CNS) progression is frequently detected in patients with favorable initial responses to first-generation EGFR-TKIs, but data are incomplete with respect to clinical features and prognostic factors of CNS failure in this population.

      We retrospectively evaluated 420 advanced non-small cell lung cancer (NSCLC) patients treated with first-generation EGFR-TKI for over 3 months. We analyzed CNS progression of these patients, defining as newly developed CNS metastases or progression of preexisting brain lesions after EGFR-TKI treatment.

      Of the 420 patients, 99 (23.6%) with CNS progression after EGFR-TKI initiation were identified. The median time to CNS progression was 12 months (95% CI 10.5–13.5). Patients with L858R mutation were more likely to experience CNS failure than those with exon 19 deletion (P = 0.008). For patients with previous brain metastases, the median time to CNS progression of patients with EGFR-TKI and local CNS therapy was significantly longer than those treated with EGFR-TKI alone (14.0 months vs. 11.2 months; P = 0.016). The median survival time after CNS progression was 11.2 months (95% CI 8.8–13.5). L858R mutation, multiple brain metastases progression and CNS with other site failures were negative prognostic factor, while localized CNS therapy was the only significant favorable prognostic factor for overall survival (OS) after CNS progression.

      For advanced NSCLC patients treated successfully with first-generation EGFR-TKI, careful monitoring for CNS progression should be considered, especially for those with L858R mutation. Localized CNS therapy should be considered for CNS progression.

      Clinical trial identification:
      This study was approved by the Institutional Review Board of West China Hospital, Sichuan University and informed consent was obtained from each patient for the use of tissue in molecular analysis

      Legal entity responsible for the study:
      West China Hospital, Sichuan UniverWest China Hospital, Sichuan University

      Has not received any funding

      All authors have declared no conflicts of interest.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.